Notable Labs Ltd
NASDAQ:NTBL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Notable Labs Ltd
NASDAQ:NTBL
|
IL |
|
S
|
S&T Holdings Ltd
HKEX:3928
|
SG |
|
A
|
Asia Hotel PCL
SET:ASIA
|
TH |
|
Duro Felguera SA
MAD:MDF
|
ES |
|
Vesync Co Ltd
HKEX:2148
|
US |
|
Franklin Covey Co
NYSE:FC
|
US |
|
Groupe Guillin SA
PAR:ALGIL
|
FR |
|
AST SpaceMobile Inc
NASDAQ:ASTS
|
US |
|
Politeknik Metal Sanayi ve Ticaret AS
IST:POLTK.E
|
TR |
|
Olympic Cards Ltd
BSE:534190
|
IN |
|
Info Edge (India) Ltd
NSE:NAUKRI
|
IN |
|
A
|
Amplefield Ltd
SGX:AOF
|
MY |
|
Sonata Software Ltd
NSE:SONATSOFTW
|
IN |
|
T
|
Toyo Shutter Co Ltd
TSE:5936
|
JP |
|
W
|
Weng Fine Art AG
XETRA:WFA
|
DE |
|
Vital Metals Ltd
ASX:VML
|
AU |
|
Sampo Corp
TWSE:1604
|
TW |
|
P
|
Prodigy PCL
SET:PDG
|
TH |
Notable Labs Ltd
Notable Labs Ltd is a IL-based company operating in Biotechnology industry. Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The firm has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The firm's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
Notable Labs Ltd is a IL-based company operating in Biotechnology industry. Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The firm has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The firm's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
